




RealRate

PHARMACEUTICAL 2020

Bioxytran INC
Rank 355 of 363



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Bioxytran INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Bioxytran INC compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 8.4% points. The greatest weakness of Bioxytran INC is the variable Stockholders Equity, reducing the Economic Capital Ratio by 130% points.

The company's Economic Capital Ratio, given in the ranking table, is 9.4%, being 229% points below the market average of 238%.

Input Variable	Value in 1000 USD
Assets, Current	220
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	1,019
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	1,124
Other Liabilities	0
Other Net Income	-227
Other Revenues	0
Property and Equipment	0
Research and Development	0
Selling, General and Administrative Expense	507

Output Variable	Value in 1000 USD
Assets	220
Liabilities	1,019
Expenses	1,631
Revenues	0
Stockholders Equity	-799
Net Income	-1,858
Comprehensive Net Income	-1,858
BaseVar	1,549
ECR before LimitedLiability	-581%
Economic Capital Ratio	9.4%